Published in Oncotarget on May 31, 2016
MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget (2016) 0.80
AKT-ions with a TWIST between EMT and MET. Oncotarget (2016) 0.76
Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer (2017) 0.75
Twist1/Dnmt3a and miR186 establish a regulatory circuit that controls inflammation-associated prostate cancer progression. Oncogenesis (2017) 0.75
SUMO1 modification of KHSRP regulates tumorigenesis by preventing the TL-G-Rich miRNA biogenesis. Mol Cancer (2017) 0.75
Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol (2005) 18.94
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol (2002) 3.82
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res (2005) 3.32
Twist is a potential oncogene that inhibits apoptosis. Genes Dev (1999) 3.14
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res (2009) 2.32
Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology (2010) 1.96
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene (2004) 1.72
Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One (2012) 1.70
MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) (2010) 1.64
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun (2012) 1.58
Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate (1998) 1.48
The metastatic cascade in prostate cancer. Surg Oncol (2006) 1.30
miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res (2012) 1.29
Expression of twist and wnt in human breast cancer. Anticancer Res (2005) 1.23
Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer (1994) 1.16
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer (2005) 1.10
PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis (2013) 1.08
Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene (2009) 1.05
MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. Cell Death Dis (2013) 1.04
Identification of microRNA transcriptome involved in human natural killer cell activation. Immunol Lett (2012) 1.04
miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene (2015) 1.00
SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. Mol Cancer (2014) 0.92
Development of prostate cancer treatment: the good news. Prostate (2004) 0.91
Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transition-inducing transcription factors. Oncotarget (2015) 0.83
Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development. Oncotarget (2015) 0.81
SUMOylation of TARBP2 regulates miRNA/siRNA efficiency. Nat Commun (2015) 0.78